Crystal form of pyrazolyl-amino-pyrimidinyl derivative, and preparation method therefor and use thereof
By preparing crystal form I of the pyrazolyl-amino-pyrimidinyl derivative, the problem of poor efficacy of existing JAK inhibitors in the treatment of atopic dermatitis was solved, achieving stability and good solubility under high temperature, high humidity and pressure conditions, thus improving the safety and therapeutic effect of the drug.
Patent Information
- Application Number
- PCT/CN2023/114936
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2023-08-25
- Publication Date
- 2024-11-28
AI Technical Summary
Existing JAK inhibitors still cannot meet clinical needs in the treatment of atopic dermatitis, and there is a need to develop safer and more effective drugs to improve treatment outcomes and patients' quality of life.
A crystalline form I of a pyrazolyl-amino-pyrimidinyl derivative is provided, which has good physical and chemical properties, solid-state stability, good solubility, low hygroscopicity and good processability in formulation. This crystalline form is obtained by preparation methods such as crystallization or cooling solution method.
Crystal form I is stable under high temperature, high humidity, and high pressure conditions, has good solubility and processability in formulation, and can effectively inhibit JAK kinase-related diseases, thereby improving drug safety and therapeutic efficacy.
Smart Images

Figure CN2023114936_28112024_PF_FP_ABST
Abstract
Description
Crystal form, preparation method and application of a pyrazolyl-amino-pyrimidinyl derivative
[0001] This application claims priority to Chinese patent application No. 2023105702936, filed on May 19, 2023, and cites the full text of the aforementioned Chinese patent application. Technical Field
[0002] The present invention relates to a crystal form, a preparation method and application of a pyrazolyl-amino-pyrimidinyl derivative. Background Art
[0003] The JAK-STAT pathway mediates the intracellular signaling of multiple cytokines in the body. Previous studies have shown that elevated levels of multiple inflammatory cytokines, such as Th1 (γ-interferon), Th2 (IL-4, IL-13, IL-31), and Th22 (IL-22), are present in the skin lesions of AD patients, suggesting that the pathogenesis of AD is closely related to the JAK-STAT pathway. IL-4 and IL-13 bind to IL-4 receptors α and γ and IL-13 receptor α1, activating JAK1 / 3 and promoting STAT3 / 6 phosphorylation. STAT3 can disrupt skin barrier integrity by downregulating proteins associated with KC differentiation; STAT6 can upregulate chemokines involved in the pathogenesis of AD, and Th0 cells differentiate into Th2 cells through the JAK1 / 3-STAT6 pathway, leading to the onset of AD. Eosinophils are one of the most important effector cells in AD. IL-5 and its receptor β chain complex participate in the regulation of eosinophil proliferation, survival, and efficacy through the JAK2-STAT1 / 5 pathway. Activated eosinophils are attracted to the skin by chemokines involved in the pathogenesis of AD released by epidermal cells in a high Th2 immune environment, further aggravating the AD condition.
[0004] Among the JAK inhibitors currently under development, those making rapid progress include Japan Tobacco's Delgocitinib (already marketed), Incyte's Ruxolitinib (already marketed), and Pfizer's Tofacitinib (Phase II). Results showed that Delgocitinib significantly improved clinical scores in patients in a Phase III clinical study for the treatment of AD. Phase II and Phase III studies of Ruxolitinib for the treatment of AD demonstrated rapid antipruritic and anti-inflammatory effects and good tolerability. In a Phase II study of Tofacitinib, 2% ointment significantly improved EASI scores in AD patients after four weeks of treatment, demonstrating good local tolerability and safety. In addition, domestic JAK inhibitors under development for the treatment of AD, including Suzhou Zejing Bio's Jaktinib Hydrochloride Cream and Jiangsu Hengrui's SHR0302 Alkaline Ointment, have also entered Phases I / II and II / III, respectively. However, current local treatments for AD still cannot meet clinical needs. Continuing to develop safer and more effective JAK inhibitors can improve the current situation of insufficient treatment drugs and enhance the treatment effect and quality of life of patients with atopic dermatitis. It has great significance and market prospects.
[0005] Preclinical studies have found that LNK01004 (its structure is shown below) is a pan-Janus kinase (JAK) inhibitor with strong inhibitory effects on JAK1, JAK2, and TYK2, and can simultaneously inhibit multiple cytokine-induced p-STAT signaling pathways in vitro and in vivo. In vitro and in vivo experimental results show that LNK01004 can inhibit the cytokine-induced p-STAT signaling pathway in immune cells. Skin application can also effectively inhibit the p-STAT signaling pathway induced by cytokines associated with psoriasis or atopic dermatitis in skin tissue. Unlike Ruxolitinib and Tofacitinib, LNK01004 can also inhibit the proliferation of keratinocytes.
[0006] Summary of the Invention
[0007] The present invention provides a crystalline form, preparation method and application of a pyrazolyl-amino-pyrimidinyl derivative. The crystalline form satisfies one or more of the following advantages: good physical and chemical properties, solid-state stability, good solubility, low hygroscopicity and good processability in formulation.
[0008] The present invention provides a crystalline form I of compound 1;
[0009] The crystalline form I uses Cu-Kα radiation, and the X-ray powder diffraction pattern expressed in 2θ has diffraction peaks at the following positions: 8.60°±0.2°, 10.25°±0.2°, 11.96°±0.2°, 14.35°±0.2°, 15.39°±0.2°, 16.59°±0.2°, 17.06°±0.2° and 18.16°±0.2°.
[0010] The present invention also provides a method for preparing the above-mentioned crystal form I, which is Scheme 1 or Scheme 2;
[0011] Scheme 1 comprises the following steps: crystallizing a methanol solution of compound 1 to obtain the crystalline form I;
[0012] Scheme 2 comprises the following steps: cooling a solution of compound 1 in tetrahydrofuran / methanol and isopropanol to obtain the crystalline form I.
[0013] The present invention also provides a pharmaceutical composition comprising the above-mentioned crystal form I and pharmaceutical excipients.
[0014] The present invention also provides a use of the above-mentioned crystal form I in the preparation of a drug for treating and / or preventing diseases associated with JAK kinase.
[0015] In one embodiment, the disease associated with JAK kinase is inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer or ovarian cancer.
[0016] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.
[0017] The reagents and raw materials used in the present invention are commercially available.
[0018] The positive progress of the present invention is that: Form I has good physical and chemical properties, good high temperature (e.g., 60°C) and high humidity (92.5% RH) stability, high pressure (10 MPa) solid-state stability, good solubility (much greater than 8 μg / mL), low hygroscopicity, uniform particle size distribution, good solid form and formulation processability, and good development prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 is the XRPD spectrum of Form I.
[0020] Figure 2 is the DSC spectrum of Form I.
[0021] FIG3 is a TGA spectrum of Form I.
[0022] Figure 4 is a PLM spectrum of Form I.
[0023] FIG5 is a SEM spectrum of Form I.
[0024] 6A and 6B are DVS spectra of Form I.
[0025] FIG7 is an XRPD spectrum of Form I before and after DVS testing. DETAILED DESCRIPTION
[0026] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.
[0027] XRPD analysis method
[0028] 1. Test Preparation
[0029] 2. Parameter setting
[0030] Note: The above parameters are established based on Bruker D8 XRPD and can be adjusted for different instruments.
[0031] 3. Testing and result reporting
[0032] Load an appropriate amount of sample (e.g., 20-50 mg, adjustable) onto the single crystal silicon plate and spread the sample evenly across the center of the plate, as shown in the figure below. If the sample contains large particles, a back-mounted sample plate can be used. If response intensity is not required, both flat and grooved single crystal silicon plates can be used; otherwise, a grooved plate should be used to maintain a consistent loading height.
[0033] If necessary, apply a thin layer of petroleum jelly or silicone oil to the surface of the single crystal silicon plate to adhere the sample, and gently tap off any excess sample. Load the sample plate into the XRPD sample holder, scan and acquire the spectrum, and report the results.
[0034] DSC test method
[0035] 1. Test Preparation
[0036] 2. Parameter setting
[0037] 3. Testing and result reporting
[0038] Take an appropriate amount of sample (do not overfill to prevent overflow during heating) and place it in an augmentation tray. Cover and seal with a capping device. Use an empty augmentation tray as a blank control. The tray and lid for the blank control should match those for the sample. Install the trays in the appropriate sample racks: the sample augmentation tray on the sample rack and the blank augmentation tray on the control rack. Select the method, use the workstation software for data processing, and report the results.
[0039] TGA test method
[0040] 1. Test Preparation
[0041] 2. Parameter setting
[0042] 3. Testing and result reporting
[0043] Place the empty sample pan in the target position on the Auto Sampler. Click "TARE" on the workstation. The instrument will automatically attach the pan, turn off the furnace, and tare. Accurately weigh approximately 2-10 mg of sample and place it on the tareed sample pan. Edit the sample information, select the method, and click "Sta" to begin sample analysis. The workstation will automatically record the curve of the sample weight percentage changing with temperature. Click "Analysis" and select "Weight change" from the drop-down menu. Click "Analyze" and the workstation will automatically calculate the sample weight loss percentage (%) and report the results.
[0044] PLM (Polarized Light Microscopy) Test Method
[0045] 1. Test Preparation
[0046] 2. Testing and result reporting
[0047] Place several particles of the sample in mineral oil (e.g., silicone oil) to form a suspension and place on a clean glass slide. Place an appropriate amount of the suspension on a glass slide and cover with a coverslip. For irregularly shaped particles, the particle size characterization must also include particle size information. The homogeneity of the powder should be verified using an appropriate magnification. Report the results of the micrographs.
[0048] Preparation and Characterization Example 1 of Form I:
[0049] LNK01004 (prepared by referring to Example 113 of CN113227074A, amorphous) (net content: 1.73 kg, 1.00 ± 0.02X) and tetrahydrofuran (15 kg, 8.7X) were added to reactor R1, the temperature was raised to 50-60°C, and stirred for 1-3 hours until all dissolved.
[0050] The temperature was controlled at 40° C., methanol (30 kg, 17X) was added, and the mixture was concentrated under reduced pressure to 4.0-6.0X. Then, methanol (4 kg, 2.3X) was added and stirred for 1-3 hours.
[0051] The suspension was filtered, and the filter cake was washed with methanol (2 kg, 1.2X). The mixture was then dried under reduced pressure at 40-50°C until the moisture and residual solvent content met the standards (tetrahydrofuran ≤ 720 ppm, methanol ≤ 5000 ppm). After drying, the mixture was sieved to yield 1.362 kg of the final product, Form I of LNK01004 (JR-C200212007-FPF21001). Its XRPD pattern is shown in Figure 1, indicating a purity of 99.91% and a yield of 90%.
[0052] Characterization of Form I
[0053] Typical characterization data collected for Form I obtained from JR-C200212007-FPF21001 are shown below. These data demonstrate that Form I is a stable, solvent-free crystalline product with very high purity, a stable melting point, solvent-free encapsulation, good morphology and particle size distribution, and no significant hygroscopicity. These properties are beneficial for the subsequent development and production of APIs and formulations.
[0054] Characterization data of Form I
[0055] Preparation Example 2 of Form I:
[0056] To reactor R1, LNK01004 (prepared with reference to Example 113 of CN113227074A, amorphous) (net content: 5 kg, 1.00 ± 0.02X) and tetrahydrofuran / methanol = 1:1 (20 kg, 4.0X) were added, the temperature was raised to 50-60°C, isopropanol (5 kg, 1.0X) was added, and the mixture was stirred for 1-3 hours until completely dissolved.
[0057] The temperature was controlled at 55° C., and isopropyl alcohol (55 kg, 11.0X) was added simultaneously and maintained for 1 to 3 hours.
[0058] The reaction temperature was lowered to 0°C over 5.0 h and maintained at 0°C for 24 h to form a suspension.
[0059] The suspension was filtered and isopropyl alcohol (10 kg, 2.0X) was added to wash the filter cake.
[0060] The mixture was dried under reduced pressure at 40-50°C until the water content and residual solvent content were within acceptable limits (tetrahydrofuran ≤ 720 ppm, methanol ≤ 5000 ppm, isopropanol ≤ 5000 ppm). After drying, the mixture was sieved to obtain 4.7 kg of the final product, LNK01004 Form I (characterization data of which were consistent with those in Example 1 for the preparation of Form I), with a purity of 100.0% and a yield of 94%.
[0061] Crystal form I effect example 1:
[0062] Water activity experiment at 1.25℃
[0063] 20 mg of Form I was weighed, 1 mL of acetone / water system with different water activities was added, and the mixture was stirred at 25° C. for 10, 12, or 22 days. The obtained solid was filtered and characterized by XRPD.
[0064] Water activity experiment at 25℃
[0065] The results of this water activity experiment show that anhydrous Form I is stable over a wide range of water activities (1%-100%) for a long period of time (up to 22 days) without converting into hydrates or other crystalline forms. This helps the formulation maintain a stable crystalline form after ingestion, facilitating temperature-dependent absorption and drug exposure.
[0066] 2. Stability test results
[0067] Crystal form I was placed under high temperature 60 ° C and high humidity 92.5% RH conditions for 30 days, and placed under light conditions 1×ICH (total illumination not less than 1.2×10 6 Lux·hr, near-ultraviolet energy not less than 200w·hr / m 2 ) and accelerated (40±2℃ / 75%±5%RH) storage for 6 months and long-term (25±2℃ / 60%±5%RH) storage for 18 months, the appearance, related substances, content on an anhydrous and solvent-free basis, moisture, crystal form, content and microbial limit results did not change.
[0068] Stability test
[0069] Example 2 of the effect of Form I: Dynamic solubility study of Form I
[0070] Approximately 20 mg of Form I was weighed and placed in a 40 mL glass vial. 10 mL of simulated gastrointestinal fluid was added and stirred at 400 rpm at 37°C. Approximately 1 mL of the suspension was removed at 1 hour, 4 hours, and 24 hours, and centrifuged at 37°C to determine the solubility of Form I at each time point. After 24 hours, the pH of the suspension was measured, and the remaining suspension was centrifuged for XRPD characterization of the remaining solid.
[0071] Study on the dynamic solubility (37°C) of Form I
[0072] The results showed that Form I had good solubility in simulated gastrointestinal fluid (far greater than 8 μg / mL), and the preparation could maintain stable absorption during subsequent formulation development and production.
[0073] Effect of Form I Example 3: Pressure Test of Form I
[0074] Approximately 10 mg of Form I (sample number: FR00970-12-SU1) was weighed and tableted using a hydraulic press at 10 MPa for 5 minutes. XRPD analysis was then performed to investigate the changes in crystallinity and crystallinity. The results showed that the dominant Form I remained stable under high pressure (10 MPa), facilitating subsequent formulation stability production.
[0075] Study on crystal transformation behavior under pressure
[0076] Example 4 of the effect of Form I: Simulated dry grinding of Form I
[0077] Approximately 10 mg of Form I (sample number: FR00970-12-SU1) was weighed and ground in a mortar for 3 minutes. XRPD analysis was then performed to investigate the crystal transformation and crystallinity changes. The results showed that Form I remained stable under dry grinding conditions, facilitating subsequent formulation production.
[0078] Simulated dry grinding experiment
[0079] Example 5: Simulated dry grinding of Form I
[0080] Approximately 10 mg of Form I (sample number: FR00970-12-SU1) was weighed and added with 40 μL of water or ethanol, respectively. The sample was then ground in a mortar for 3 minutes. XRPD analysis was performed to investigate the crystal transformation and crystallinity changes. The results showed that the dominant Form I remained stable under wet grinding conditions, facilitating subsequent formulation production.
[0081] Simulated wet grinding experiment
[0082] Effect of Form I Example 6: Pharmacodynamic Data of Form I
[0083] This study used a migration assay to determine the half-inhibitory concentration (IC50) values of Form I of the compound LNK01004, ruxolitinib, tofacitinib, and upadacitinib against JAK1, JAK2, JAK3, and TYK2 kinase activity. In the assay, Form I of the compound LNK01004, ruxolitinib, tofacitinib, and upadacitinib were tested against JAK1, JAK2, JAK3, and TYK2 kinases at a starting concentration of 10 μM, using a 3-fold serial dilution series for a total of 10 concentrations in duplicate wells. The ATP concentration was 1 mM. The test results are shown in the table below:
[0084] The half-inhibitory concentration (IC50) value of Form I on the kinase activity of JAK1, JAK2, JAK3, and TYK2
[0085] The experimental results show that Form I of the compound LNK01004 has stronger kinase activity inhibition ability in JAK1, JAK2, JAK3, and TYK2 activity tests than ruxolitinib, tofacitinib, and upadacitinib, demonstrating that Form I of LNK01004 has better pharmaceutical properties at the same concentration and dosage.
Claims
1. A crystalline form I of compound 1, It is characterized in that The crystalline form I uses Cu-Kα radiation, and the X-ray powder diffraction pattern represented by 2θ has diffraction peaks at the following positions: 8.60°±0.2°, 10.25°±0.2°, 11.96°±0.2°, 14.35°±0.2°, 15.39°±0.2°, 16.59°±0.2°, 17.06°±0.2° and 18.16°±0.2°; 2. The crystalline form I according to claim 1, It is characterized in that The crystal form I satisfies one or more of the following conditions: (1) The X-ray powder diffraction pattern of the crystalline form I expressed in 2θ angles further has diffraction peaks at one or more of the following positions: 12.77°±0.2°, 13.48°±0.2°, 14.04°±0.2°, 17.27°±0.2°, 18.83°±0.2°, 20.52°±0.2°, 20.77°±0.2°, 21.45°±0.2°, 22.12°±0.2°, 22.79°±0.2°, 23.55°±0.2°, 24.04°±0.2°, 24.40° ± 0.2°, 25.08°±0.2°, 25.87°±0.2°, 26.51°±0.2°, 26.73°±0.2°, 26.89°±0.2°, 27.36°±0.2° and 28.29°±0.2°; preferably, there are diffraction peaks at one or more of the following positions: 28.93°±0.2°, 29.42°±0.2°, 30.63°±0.2°, 33.00°±0.2°, 33.37°±0.2°, 34.43°±0.2° and 37.09°±0.2°; (2) The differential scanning calorimetry of the crystalline form I has an endothermic peak at 207.4°C to 209.2°C; (3) The thermogravimetric analysis of the crystal form I ranges from 30.07°C to 208.96°C, and the weight loss is 0.0%.
3. The crystalline form I as claimed in claim 2, It is characterized in that The crystal form I satisfies one or more of the following conditions: (1) The X-ray powder diffraction pattern of the crystalline form I expressed at 2θ angle has diffraction peaks as shown in the following table: (2) The differential scanning calorimetry of the Form I has an endothermic peak at 207.4°C to 209.2°C, and the heat of fusion is 123.76 J / g; (3) The thermogravimetric analysis diagram of the crystal form I is basically as shown in Figure 3.
4. The crystalline form I as claimed in claim 3, It is characterized in that The crystal form I satisfies one or more of the following conditions: (1) The X-ray powder diffraction pattern of the crystalline form I expressed at 2θ angle is substantially as shown in FIG1 ; (2) The differential scanning calorimetry diagram of the crystal form I is basically as shown in Figure 2.
5. A method for preparing the crystalline form I according to any one of claims 1 to 4, It is characterized in that It is Option 1 or Option 2; wherein, Scheme 1 comprises the following steps: crystallizing a methanol solution of compound 1 to obtain the crystalline form I; Scheme 2 comprises the following steps: cooling a solution of compound 1 in tetrahydrofuran / methanol and isopropanol to obtain the crystalline form I.
6. The method for preparing the crystalline form I according to claim 5, It is characterized in that The preparation method meets one or more of the following conditions: (1) In the first embodiment, during the crystallization, the mass of the solution is (1:6)-(1:8.5) of the mass of the compound 1; preferably (1:6.3)-(1:8.3); (2) The first scheme comprises the following operations: adding methanol to a solution of compound 1 and tetrahydrofuran at 40° C., concentrating, adding methanol again to the concentrate, stirring, and crystallizing to obtain the crystalline form I; Wherein, the temperature at which the compound 1 is dissolved in the tetrahydrofuran to form a solution is preferably 50-60°C; The mass ratio of the compound 1 to the tetrahydrofuran is preferably (1:8)-(1:9); more preferably 1:8.7; The mass ratio of the compound 1 to the methanol added for the first time is preferably (1:16)-(1:18); more preferably 1:17; The mass of the concentrated solution is preferably 4-6 times the mass of the compound 1, more preferably 5 times; The mass ratio of the compound 1 to the methanol added for the second time is preferably (1:2)-(1:3); more preferably 1:2.3; (3) The scheme 1 further comprises the following post-processing steps: filtering, washing, drying under reduced pressure, and sieving to obtain the crystal form I; (4) In scheme 2, the mass ratio of compound 1 to tetrahydrofuran / methanol is (1:3)-(1:5); preferably 1:4; (5) In the second scheme, the mass ratio of tetrahydrofuran to methanol in the tetrahydrofuran / methanol is (2:1)-(1:2); preferably 1:1; (6) In scheme 2, the mass ratio of compound 1 to isopropanol is (1:11)-(1:13); preferably 1:12; (7) In scheme 2, the temperature at which compound 1 is dissolved in tetrahydrofuran / methanol and isopropanol is 50-60°C, preferably 55°C; (8) In scheme 2, the cooling is to reduce the temperature to 0-5°C, preferably 0°C; (9) In scheme 2, the insulation time after cooling is 15-30 hours, more preferably 24 hours; (10) The second scheme also includes the following post-processing steps: filtering, washing, drying under reduced pressure, and sieving to obtain the crystal form I.
7. The method for preparing the crystalline form I according to claim 6, It is characterized in that The second scheme comprises the following operations: heating the compound 1 and tetrahydrofuran / methanol, adding isopropanol to dissolve, adding isopropanol again, cooling to form a suspension, and obtaining the crystal form I.
8. A pharmaceutical composition comprising the crystalline form I according to any one of claims 1 to 4 and a pharmaceutical excipient.
9. Use of the crystalline form I according to any one of claims 1 to 4 in the preparation of a drug for treating and / or preventing a disease associated with JAK kinase; The diseases associated with JAK kinase are inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, myelofibrosis, breast cancer or ovarian cancer.
10. Use of the crystalline form I according to any one of claims 1 to 4 in the preparation of a drug for treating and / or preventing a disease, It is characterized in that The disease is inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, myelofibrosis, breast cancer or ovarian cancer.
Citation Information
Patent Citations
Pyridine compounds and aza analogues thereof as TYK2 inhibitors
CN103298794A
Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN113227074A
Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN113993861A
Protein kinase inhibitors and uses thereof
US20040106615A1
Protein kinase inhibitors and uses thereof
WO2004016597A2
